Anti-inflammatory and anti-senescence drug development
From 2010 through 2015, Aisa Therapeutics held the same core conviction without meaningful deviation: naturally occurring plant-derived molecules can modulate vascular-endothelium inflammation pathways, and that modulation addresses chronic inflammatory diseases in the GI tract, joints, and cardiovascular system. The founding framing in May 2010 already contained every load-bearing element — the vascular-endothelium target, the edible-plant sourcing, the anti-senescence claim, the dual pharma/nutraceutical positioning, and the animal-health extension. None of those elements disappeared or reversed across any subsequent snapshot. The only detectable shift between 2010 and 2012 is one of specificity rather than direction. The 2012 snapshot names concrete disease areas — dermatitis, colitis — that the earlier snapshots left implicit under the umbrella of 'chronic inflammatory diseases.' The 2012 version also explicitly labels the molecules as 'anti-inflammatory' as a distinct property alongside 'anti-senescence,' where the 2010 and 2011 versions foregrounded anti-senescence and treated the anti-inflammatory effect as downstream. That is a presentational sharpening, not a belief change. The 2015 snapshot compresses the language again without adding new claims, which suggests the company's public messaging stabilised rather than that its science moved on. The absence of clinical-trial language, mechanism-of-action depth, or any named compound across all four snapshots means we cannot tell from this source set whether the underlying R&D programme evolved — only that the stated thesis did not. The evidence base is thin in a specific way: all four sources are website snapshots of marketing copy, separated by gaps of 7–36 months, with no trial registrations, publications, or investor materials in the record. The divergence score reflects genuine stability of stated belief, but that stability might also reflect static copy rather than a living, tested conviction.